PharmAust CEO's sayanora triggers stock plunge
Clinical-stage biotechnology company, PharmAust shares plunged 24 per cent so this morning, following the resignation of its CEO, Dr. Michael Thurn.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
SUM | Ann: Summerset Annual Meeting - Chairman and CEO Addresses | 11:30 | 0 | 19 | |||
|
|||||||
SUM | Ann: 1Q24 Metrics - Sales of Occupation Rights | 09/04/24 | 0 | 65 | |||
|
|||||||
SUM | Ann: Ongoing Disclosure Notices | 28/03/24 | 0 | 51 | |||
|
|||||||
SUM | Ann: ASX Appendix 2A | 22/03/24 | 0 | 46 | |||
|
|||||||
SUM | Ann: Notice of Allotment of Securities | 22/03/24 | 0 | 54 | |||
|
|||||||
SUM | Ann: Notice of Meeting | 22/03/24 | 0 | 53 | |||
|
|||||||
SUM | Ann: ASX Appendix 3A.1 - Updated for DRP Strike Price and AUD FX | 19/03/24 | 0 | 53 | |||
|
|||||||
SUM | Ann: DRP Strike Price and AUD FX Rate for 2023 Final Dividend | 19/03/24 | 0 | 50 | |||
|
See All Discussions